{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T23:49:02Z","timestamp":1769471342166,"version":"3.49.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226120\/Z\/22\/Z"],"award-info":[{"award-number":["226120\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The emergence of SARS-CoV-2 variants that evade immune responses poses challenges to effective prevention. We prospectively enrolled 111 COVID-19 patients in Thailand (2021-2022), who received homologous or heterologous vaccines or were unvaccinated. Plasma neutralizing antibody (nAb) levels against SARS-CoV-1 and 13 SARS-CoV-2 strains were measured using a multiplex surrogate virus neutralization test (sVNT) assay within a year. nAb levels increased in two weeks, showing strong inhibition against ancestral SARS-CoV-2 and non-omicron variants, but not against SAR-CoV-1 and lower responses to omicron variants. nAb levels declined by the day 60. Breakthrough patients with heterologous vaccines had higher nAb levels compared to other groups. nAb levels were lower in breakthrough patients with pneumonia than those with other conditions. Notably, breakthrough patients aged \u226560 showed rapid declines in antibody levels. Our findings highlight diverse immune responses influenced by immunization, age, and clinical conditions, underscoring the need for tailored vaccination strategies against evolving variants.<\/jats:p>","DOI":"10.1038\/s41598-025-33388-7","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:18:22Z","timestamp":1767493102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022)"],"prefix":"10.1038","volume":"16","author":[{"given":"Prapassorn","family":"Poolchanuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vichapon","family":"Tiacharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adul","family":"Dulsuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rungnapa","family":"Phunpang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakkaphan","family":"Runcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thitiya","family":"Boonprakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onura","family":"Hemtong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchada","family":"Chowplijit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vachara","family":"Chuapaknam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanaya","family":"Siripoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Watcharapong","family":"Piyaphanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le Van","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Dunachie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Wah","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Fa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasun","family":"Chantratita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viravarn","family":"Luvira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narisara","family":"Chantratita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SEACOVARIANTS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen To","family":"Anh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thi Thu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truong Hoang Chau","family":"Truc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thi Han","family":"Ny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Duong Kim","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le Kim","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lam Anh","family":"Nguyet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cao Thu","family":"Thuy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le Nguyen Truc","family":"Nhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran Tan","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen To","family":"Anh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lam Minh","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu Thi Ty","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pham Tieu","family":"Kieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vo Tan","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thi","family":"Thao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu Duy","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran Chieu","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CLouise","family":"Thwaites","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Thwaites","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.Rogier","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinh Son","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raph L","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuraj","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juthathip","family":"Mongkolsapaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Screaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiete","family":"Dijokaite-Guraliuc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raksha","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyada","family":"Supasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneeswaran","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EYvonne","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kronsteiner-Dobramysl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Zewdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee Chee","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beng Lee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwarti","family":"Suwarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanie","family":"Tayipto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Simarmata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragil","family":"Dien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanwisa","family":"Dejnirattisai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warangkana","family":"Chantima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apirak","family":"Junpirom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sopon","family":"Iamsirithaworn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P.J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phaik Yeong","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tassawan","family":"Poomchaichote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanpong","family":"Boonthaworn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nghiem My","family":"Ngoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"33388_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017 (2020).","journal-title":"N. Engl. J. Med."},{"key":"33388_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18126312","author":"MA Farrag","year":"2021","unstructured":"Farrag, M. A. et al. SARS-CoV-2: an Overview of virus genetics, transmission, and immunopathogenesis. Int. J. Environ. Res. Public Health https:\/\/doi.org\/10.3390\/ijerph18126312 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"33388_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.552909","volume":"11","author":"Z Abdelrahman","year":"2020","unstructured":"Abdelrahman, Z., Li, M. & Wang, X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses. Front. Immunol. 11, 552909. https:\/\/doi.org\/10.3389\/fimmu.2020.552909 (2020).","journal-title":"Front. Immunol."},{"key":"33388_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol 19, 409\u2013424. https:\/\/doi.org\/10.1038\/s41579-021-00573-0 (2021).","journal-title":"Nat. Rev. Microbiol"},{"key":"33388_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41598-023-50856-0","volume":"14","author":"J Puenpa","year":"2024","unstructured":"Puenpa, J., Chansaenroj, J., Suwannakarn, K. & Poovorawan, Y. Genomic epidemiology and evolutionary analysis during XBB.1.16-predominant periods of SARS-CoV-2 omicron variant in Bangkok, Thailand: December 2022\u2013August 2023. Sci. Rep. 14, 645. https:\/\/doi.org\/10.1038\/s41598-023-50856-0 (2024).","journal-title":"Sci. Rep."},{"key":"33388_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/s1473-3099(23)00278-5","volume":"23","author":"D Yamasoba","year":"2023","unstructured":"Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis. 23, 655\u2013656. https:\/\/doi.org\/10.1016\/s1473-3099(23)00278-5 (2023).","journal-title":"Lancet Infect Dis."},{"key":"33388_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100849","volume":"37","author":"R Pung","year":"2023","unstructured":"Pung, R. et al. Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore. Lancet Reg. Health West Pac. 37, 100849. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100849 (2023).","journal-title":"Lancet Reg. Health West Pac."},{"key":"33388_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713573","author":"F Scarpa","year":"2023","unstructured":"Scarpa, F. et al. Integrative genome-based survey of the SARS-CoV-2 omicron XBB.1.16 variant. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241713573 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"33388_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101533","author":"AA Pochtovyi","year":"2023","unstructured":"Pochtovyi, A. A. et al. In vitro efficacy of antivirals and monoclonal antibodies against SARS-CoV-2 omicron lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines11101533 (2023).","journal-title":"Vaccines (Basel)"},{"key":"33388_CR10","doi-asserted-by":"publisher","first-page":"113193","DOI":"10.1016\/j.celrep.2023.113193","volume":"42","author":"JN Faraone","year":"2023","unstructured":"Faraone, J. N. et al. Continued evasion of neutralizing antibody response by omicron XBB.1.16. Cell Rep. 42, 113193. https:\/\/doi.org\/10.1016\/j.celrep.2023.113193 (2023).","journal-title":"Cell Rep."},{"key":"33388_CR11","doi-asserted-by":"publisher","first-page":"e20916","DOI":"10.1016\/j.heliyon.2023.e20916","volume":"9","author":"A Lagare","year":"2023","unstructured":"Lagare, A. et al. First identification of the SARS-COV-2\/XBB.1.5 sublineage among indigenous COVID-19 cases through the influenza sentinel surveillance system in Niger. Heliyon 9, e20916. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20916 (2023).","journal-title":"Heliyon"},{"key":"33388_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/joim.13372","volume":"291","author":"X Castro Dopico","year":"2022","unstructured":"Castro Dopico, X., Ols, S., Lor\u00e9, K. & Karlsson Hedestam, G. B. Immunity to SARS-CoV-2 induced by infection or vaccination. J. Intern. Med. 291, 32\u201350. https:\/\/doi.org\/10.1111\/joim.13372 (2022).","journal-title":"J. Intern. Med."},{"key":"33388_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40779-021-00342-3","volume":"8","author":"NY Pang","year":"2021","unstructured":"Pang, N. Y., Pang, A. S., Chow, V. T. & Wang, D. Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil. Med. Res. 8, 47. https:\/\/doi.org\/10.1186\/s40779-021-00342-3 (2021).","journal-title":"Mil. Med. Res."},{"key":"33388_CR14","doi-asserted-by":"publisher","first-page":"100660","DOI":"10.1016\/j.lanwpc.2022.100660","volume":"32","author":"R Zhou","year":"2023","unstructured":"Zhou, R. et al. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. Lancet Reg. Health West Pac. 32, 100660. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100660 (2023).","journal-title":"Lancet Reg. Health West Pac."},{"key":"33388_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.16.524244","author":"P Qu","year":"2023","unstructured":"Qu, P. et al. Extraordinary evasion of neutralizing antibody response by omicron XBB.1.5, CH.1.1 and CA.3.1 variants. bioRxiv https:\/\/doi.org\/10.1101\/2023.01.16.524244 (2023).","journal-title":"bioRxiv"},{"key":"33388_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00465-22","volume":"8","author":"P Poolchanuan","year":"2023","unstructured":"Poolchanuan, P. et al. Dynamics of different classes and subclasses of antibody responses to severe acute respiratory syndrome coronavirus 2 Variants after coronavirus disease 2019 and CoronaVac vaccination in Thailand. mSphere 8, e0046522. https:\/\/doi.org\/10.1128\/msphere.00465-22 (2023).","journal-title":"mSphere"},{"key":"33388_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4269\/ajtmh.21-0849","volume":"106","author":"NVV Chau","year":"2022","unstructured":"Chau, N. V. V. et al. Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in vietnamese health-care workers. Am. J. Trop. Med. Hyg. 106, 556\u2013561. https:\/\/doi.org\/10.4269\/ajtmh.21-0849 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"33388_CR18","doi-asserted-by":"crossref","unstructured":"Sinto, R., Utomo, D., Suwarti, Nelwan, E., Surendra, H., Natasha, C., Fransiska, Theresia, D., Ranitria, A.F., Subekti, D., et al. Serum anti-spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine. medRxiv. (2021)","DOI":"10.1101\/2021.12.24.21268360"},{"key":"33388_CR19","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/infdis\/jiac092","volume":"226","author":"S Assawakosri","year":"2022","unstructured":"Assawakosri, S. et al. Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. J. Infect. Dis. 226, 1372\u20131381. https:\/\/doi.org\/10.1093\/infdis\/jiac092 (2022).","journal-title":"J. Infect. Dis."},{"key":"33388_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.01.21252652","author":"J Bernal","year":"2021","unstructured":"Bernal, J. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv. https:\/\/doi.org\/10.1101\/2021.03.01.21252652 (2021).","journal-title":"medRxiv."},{"key":"33388_CR21","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/s0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 398, 1407\u20131416. https:\/\/doi.org\/10.1016\/s0140-6736(21)02183-8 (2021).","journal-title":"Lancet"},{"key":"33388_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s42003-022-03849-0","volume":"5","author":"CM Trombetta","year":"2022","unstructured":"Trombetta, C. M. et al. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations. Commun. Biol. 5, 903. https:\/\/doi.org\/10.1038\/s42003-022-03849-0 (2022).","journal-title":"Commun. Biol."},{"key":"33388_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","volume":"23","author":"VG Hall","year":"2022","unstructured":"Hall, V. G. & Ferreira, V. H. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat. Immunol. 23, 380\u2013385. https:\/\/doi.org\/10.1038\/s41590-021-01126-6 (2022).","journal-title":"Nat. Immunol."},{"key":"33388_CR24","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1038\/s41467-021-27410-5","volume":"12","author":"G Amirthalingam","year":"2021","unstructured":"Amirthalingam, G. et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat. Commun. 12, 7217. https:\/\/doi.org\/10.1038\/s41467-021-27410-5 (2021).","journal-title":"Nat. Commun."},{"key":"33388_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/imr.12897","volume":"296","author":"IG Ovsyannikova","year":"2020","unstructured":"Ovsyannikova, I. G., Haralambieva, I. H., Crooke, S. N., Poland, G. A. & Kennedy, R. B. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol. Rev. 296, 205\u2013219. https:\/\/doi.org\/10.1111\/imr.12897 (2020).","journal-title":"Immunol. Rev."},{"key":"33388_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255796","volume":"16","author":"S Tandhavanant","year":"2021","unstructured":"Tandhavanant, S. et al. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE 16, e0255796. https:\/\/doi.org\/10.1371\/journal.pone.0255796 (2021).","journal-title":"PLoS ONE"},{"key":"33388_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42754-2","author":"J Chansaenroj","year":"2023","unstructured":"Chansaenroj, J. et al. Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-023-42754-2 (2023).","journal-title":"Sci. Rep."},{"key":"33388_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijid.2021.09.021","volume":"112","author":"V Vacharathit","year":"2021","unstructured":"Vacharathit, V. et al. SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile. Int. J. Infect Dis. 112, 227\u2013234. https:\/\/doi.org\/10.1016\/j.ijid.2021.09.021 (2021).","journal-title":"Int. J. Infect Dis."},{"key":"33388_CR29","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.vaccine.2022.04.043","volume":"40","author":"N Wanlapakorn","year":"2022","unstructured":"Wanlapakorn, N. et al. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data. Vaccine 40, 3203\u20133209. https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.043 (2022).","journal-title":"Vaccine"},{"key":"33388_CR30","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1038\/s41564-022-01246-1","volume":"7","author":"CW Tan","year":"2022","unstructured":"Tan, C. W. et al. SARS-CoV-2 omicron variant emerged under immune selection. Nat. Microbiol. 7, 1756\u20131761. https:\/\/doi.org\/10.1038\/s41564-022-01246-1 (2022).","journal-title":"Nat. Microbiol."},{"key":"33388_CR31","doi-asserted-by":"publisher","first-page":"e02314","DOI":"10.1128\/spectrum.02314-22","volume":"11","author":"M Graninger","year":"2023","unstructured":"Graninger, M. et al. Comprehensive comparison of seven SARS-CoV-2-specific surrogate virus neutralization and anti-spike igg antibody assays using a live-virus neutralization assay as a reference. Microbiol. Spectr. 11, e02314-02322. https:\/\/doi.org\/10.1128\/spectrum.02314-22 (2023).","journal-title":"Microbiol. Spectr."},{"key":"33388_CR32","doi-asserted-by":"publisher","first-page":"1184362","DOI":"10.3389\/fimmu.2023.1184362","volume":"14","author":"D Cantoni","year":"2023","unstructured":"Cantoni, D. et al. Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Front. Immunol. 14, 1184362 (2023).","journal-title":"Front. Immunol."},{"key":"33388_CR33","doi-asserted-by":"publisher","first-page":"15831","DOI":"10.1038\/s41598-025-98627-3","volume":"15","author":"P Poolchanuan","year":"2025","unstructured":"Poolchanuan, P. et al. Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients. Sci. Rep. 15, 15831. https:\/\/doi.org\/10.1038\/s41598-025-98627-3 (2025).","journal-title":"Sci. Rep."},{"key":"33388_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction. Nat. Biotechnol. 38, 1073\u20131078. https:\/\/doi.org\/10.1038\/s41587-020-0631-z (2020).","journal-title":"Nat. Biotechnol."},{"key":"33388_CR35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1186\/s12879-024-09999-2","volume":"24","author":"W Khongsiri","year":"2024","unstructured":"Khongsiri, W. et al. Associations between clinical data, vaccination status, antibody responses, and post-COVID-19 symptoms in Thais infected with SARS-CoV-2 delta and omicron variants: a 1-year follow-up study. BMC Infect. Dis. 24, 1116. https:\/\/doi.org\/10.1186\/s12879-024-09999-2 (2024).","journal-title":"BMC Infect. Dis."},{"key":"33388_CR36","doi-asserted-by":"publisher","first-page":"102890","DOI":"10.1016\/j.ebiom.2020.102890","volume":"58","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine 58, 102890. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102890 (2020).","journal-title":"EBioMedicine"},{"key":"33388_CR37","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.26355\/eurrev_202007_22293","volume":"24","author":"P Rat","year":"2020","unstructured":"Rat, P., Olivier, E. & Dutot, M. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential. Eur. Rev. Med. Pharmacol. Sci. 24, 7880\u20137885. https:\/\/doi.org\/10.26355\/eurrev_202007_22293 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"33388_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.784303","volume":"8","author":"A Sobitan","year":"2021","unstructured":"Sobitan, A. et al. Computational saturation mutagenesis of sars-cov-1 spike glycoprotein: stability, binding affinity, and comparison with SARS-CoV-2. Front. Mol. Biosci. 8, 784303. https:\/\/doi.org\/10.3389\/fmolb.2021.784303 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"33388_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41392-023-01495-4","volume":"8","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection. Signal Transduct. Target Ther. 8, 252. https:\/\/doi.org\/10.1038\/s41392-023-01495-4 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"33388_CR40","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1002\/jmv.27927","volume":"94","author":"S Kumar","year":"2022","unstructured":"Kumar, S., Karuppanan, K. & Subramaniam, G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: a comparative sequence and structural-based computational assessment. J. Med. Virol. 94, 4780\u20134791. https:\/\/doi.org\/10.1002\/jmv.27927 (2022).","journal-title":"J. Med. Virol."},{"key":"33388_CR41","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMc2200133","volume":"386","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N. Engl. J. Med. 386, 1288\u20131290. https:\/\/doi.org\/10.1056\/NEJMc2200133 (2022).","journal-title":"N. Engl. J. Med."},{"key":"33388_CR42","doi-asserted-by":"publisher","DOI":"10.12659\/msm.939580","volume":"29","author":"DV Parums","year":"2023","unstructured":"Parums, D. V. Editorial: the XBB.1.5 ('Kraken\u2019) subvariant of omicron SARS-CoV-2 and its rapid global spread. Med. Sci. Monit. 29, e939580. https:\/\/doi.org\/10.12659\/msm.939580 (2023).","journal-title":"Med. Sci. Monit."},{"key":"33388_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.chom.2022.07.006","volume":"30","author":"C Pastorio","year":"2022","unstructured":"Pastorio, C. et al. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2. Cell Host Microbe 30, 1255-1268.e1255. https:\/\/doi.org\/10.1016\/j.chom.2022.07.006 (2022).","journal-title":"Cell Host Microbe"},{"key":"33388_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105699","volume":"170","author":"A Hossain","year":"2022","unstructured":"Hossain, A., Akter, S., Rashid, A. A., Khair, S. & Alam, A. Unique mutations in SARS-CoV-2 Omicron subvariants\u2019 non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. Microb. Pathog. 170, 105699. https:\/\/doi.org\/10.1016\/j.micpath.2022.105699 (2022).","journal-title":"Microb. Pathog."},{"key":"33388_CR45","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","volume":"12","author":"AK Wheatley","year":"2021","unstructured":"Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162. https:\/\/doi.org\/10.1038\/s41467-021-21444-5 (2021).","journal-title":"Nat. Commun."},{"key":"33388_CR46","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"33388_CR47","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","volume":"30","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe 30, 880-886.e884. https:\/\/doi.org\/10.1016\/j.chom.2022.03.029 (2022).","journal-title":"Cell Host Microbe"},{"key":"33388_CR48","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s10875-022-01325-2","volume":"42","author":"G Lamacchia","year":"2022","unstructured":"Lamacchia, G. et al. Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization. J. Clin. Immunol. 42, 1379\u20131391. https:\/\/doi.org\/10.1007\/s10875-022-01325-2 (2022).","journal-title":"J. Clin. Immunol."},{"key":"33388_CR49","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/infdis\/jiad320","volume":"228","author":"LF Duarte","year":"2023","unstructured":"Duarte, L. F. et al. Differential severe acute respiratory syndrome coronavirus 2-specific humoral response in inactivated virus-vaccinated, convalescent, and breakthrough-infected subjects. J. Infect. Dis. 228, 857\u2013867. https:\/\/doi.org\/10.1093\/infdis\/jiad320 (2023).","journal-title":"J. Infect. Dis."},{"key":"33388_CR50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521\u2013529. https:\/\/doi.org\/10.1016\/s0140-6736(22)00094-0 (2022).","journal-title":"Lancet"},{"key":"33388_CR51","doi-asserted-by":"publisher","first-page":"1390.e1391","DOI":"10.1016\/j.cmi.2022.04.019","volume":"28","author":"S Bae","year":"2022","unstructured":"Bae, S. et al. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity. Clin. Microbiol. Infect. 28, 1390.e1391-1390.e1397. https:\/\/doi.org\/10.1016\/j.cmi.2022.04.019 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"33388_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.medj.2021.12.004","volume":"3","author":"NKH Khoo","year":"2022","unstructured":"Khoo, N. K. H. et al. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med 3, 104-118.e104. https:\/\/doi.org\/10.1016\/j.medj.2021.12.004 (2022).","journal-title":"Med"},{"key":"33388_CR53","doi-asserted-by":"publisher","first-page":"108474","DOI":"10.1016\/j.isci.2023.108474","volume":"26","author":"KE Lineburg","year":"2023","unstructured":"Lineburg, K. E. et al. iScience 26, 108474. https:\/\/doi.org\/10.1016\/j.isci.2023.108474 (2023).","journal-title":"iScience"},{"key":"33388_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.20411\/pai.v8i1.613","volume":"8","author":"S Datwani","year":"2023","unstructured":"Datwani, S. et al. Dynamics of T-cell responses following COVID-19 mRNA vaccination and breakthrough infection in older adults. Pathog. Immun. 8, 117\u2013135. https:\/\/doi.org\/10.20411\/pai.v8i1.613 (2023).","journal-title":"Pathog. Immun."},{"key":"33388_CR55","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"33388_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111. https:\/\/doi.org\/10.1016\/s0140-6736(20)32661-1 (2021).","journal-title":"Lancet"},{"key":"33388_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080918","author":"D Fabricius","year":"2021","unstructured":"Fabricius, D. et al. mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines9080918 (2021).","journal-title":"Vaccines (Basel)"},{"key":"33388_CR58","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12879-020-05231-z","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou, X., Zhou, J. & Zhao, J. Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report. BMC Infect. Dis. 20, 500. https:\/\/doi.org\/10.1186\/s12879-020-05231-z (2020).","journal-title":"BMC Infect. Dis."},{"key":"33388_CR59","doi-asserted-by":"publisher","first-page":"660019","DOI":"10.3389\/fimmu.2021.660019","volume":"12","author":"P Ahluwalia","year":"2021","unstructured":"Ahluwalia, P. et al. Infection and immune memory: variables in robust protection by vaccines against SARS-CoV-2. Front. Immunol. 12, 660019 (2021).","journal-title":"Front. Immunol."},{"key":"33388_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030546","author":"IV Kostopoulos","year":"2021","unstructured":"Kostopoulos, I. V. et al. Recovery of innate immune cells and persisting alterations in adaptive immunity in the peripheral blood of convalescent plasma donors at eight months post SARS-CoV-2 infection. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms9030546 (2021).","journal-title":"Microorganisms"},{"key":"33388_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(24)00155-5","author":"DL Wannigama","year":"2024","unstructured":"Wannigama, D. L. et al. Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(24)00155-5 (2024).","journal-title":"Lancet Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33388-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33388-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33388-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:19:09Z","timestamp":1769433549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33388-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33388"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33388-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3408"}}